Endocervical adenocarcinomas. Cytological, histological, and molecular diagnostics

Author:

Grigoruk O. G.1ORCID,Moskvina T. A.1,Tsoy D. A.1,Stepanova A. S.1,Bazulina L. M.1,Sigitova E. S.1,Ponomareva T. V.1,Ilinskiy V. K.1,Bryleva Yu. A.1,Samuylenkova O. V.1,Bakharev S. Yu.1,Pupkova E. E.1,Baron A. V.1,Fedoskina A. V.1

Affiliation:

1. Altai Regional Oncology Dispensary; Altai State Medical University, Ministry of Health of Russia

Abstract

This study was undertaken to analyze the effectiveness of cytological diagnostics of endocervical adenocarcinomas. We compared conventional liquid-based cytology, histology, immunohistochemistry, and molecular testing. A total of 25 endocervical adenocarcinomas, including endocervical adenocarcinomas in situ, were diagnosed using cytological methods over a year. Liquid-based cytology ensured better detection of glandular differentiation signs than conventional cytology. After molecular testing for human papillomavirus (HPV), we performed retrospective analysis of cytological characteristics of all endocervical adenocarcinomas (n = 15).We identified specific cellular characteristics of HPV-associated typical and mucinous adenocarcinomas. We also observed 1 case of non-HPV-related clear-cell and 1 case of non-HPV-related mesonephral adenocarcinoma.Our findings suggest that endocervical adenocarcinomas are a heterogeneous group of tumors. Endocervical adenocarcinomas accounted for 10.7 % of all primary cervical carcinomas (n = 214). Eighty percent of all endocervical adenocarcinomas were HPV-related, whereas the remaining 20 % were HPV-negative. We found no cytological differences between invasive endocervical adenocarcinomas and adenocarcinomas in situ.Mutations detected in some of the patients are an important diagnostic criterion that specifies whether the tumor is rare. 

Publisher

Publishing House ABV Press

Subject

Pharmacology (medical),Obstetrics and Gynecology,Radiology, Nuclear Medicine and imaging,Oncology,Surgery

Reference30 articles.

1. Situtation with cancer care in Russia in 2020. Ed. by A.D. Kaprin, V.V. Starinskiy, A.O. Shakhzodova. Moscow: P.A. Herzen Moscow Oncology Research Institute – a branch of the National Medical Research Radiological Center, Ministry of Health of Russia, 2021. 239 p. (In Russ.).

2. Ashrafyan L.A., Kiselev V.I., Kuznetsov I.N. et al. Cervical cancer: problems of its prevention and screening in the Russian Federation. Doktor.ru = Doctor.ru. 2019;11(166):50– 4. (In Russ.). DOI: 10.31550/1727-2378-2019-166-11-50-54.

3. WHO Classification of Tumours Editorial Board. WHO Classification of Female Genital Tumours (Vol 4), 5th edn. Lyon: International Agency for Research on Cancer, 2020. 631 p.

4. Wang S.S., Sherman M.E., Hildesheim A. et al. Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in United States for 1976–2000. Cancer 2004;100:1035–44. DOI: 10.1002/cncr.20064.

5. Vn der Horst J., Siebers A.G., Bulten J. et al. Increasing incidence of invasive and in situ cervical adenocarcinoma in the Netherlands during 2004–2013. Cancer Med 2017;6:416–23. DOI: 10.1002/cam4.971.

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3